• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Oklo Stock Gets Reactor Approval

    Simply Wall St·10/18/2026 02:34:22
    语音播报
    • Oklo announced progress on two fronts: advancing its Groves 2 Forge isotope facility under a U.S. Department of Energy initiative and securing Nuclear Regulatory Commission approval of the Principal Design Criteria for its Aurora Powerhouse reactor.
    • The combination of medical isotope production capabilities and a clearer regulatory path for compact reactors points directly to Oklo’s effort to build multiple long term revenue streams beyond power sales alone.
    • We will now look at how Oklo’s investment narrative could shift as Groves 2 Forge targets lutetium 177 for radiopharmaceutical supply.

    Scan 16 nuclear energy infrastructure stocks that echo Oklo's push into compact reactors and isotope production, and see which other nuclear infrastructure plays are building momentum around similar long term themes.

    Oklo Investment Narrative Recap

    Owning Oklo means backing an early stage nuclear operator that is still pre revenue, running quarterly operating losses of $36.3 million and using $48.7 million in operating cash year to date. The thesis hinges on Oklo turning a reported 14 gigawatt pipeline and its fuel cycle projects into contracted, operating assets. The Groves 2 Forge update and Aurora design criteria approval both speak to execution steps, but do not change that basic setup.

    In the near term, the most important catalyst remains getting first reactors and associated fuel facilities into authorized construction and then commercial operation, so counterparties can sign firm, long dated agreements. The biggest risk is delay, whether from regulation, capital intensity, fuel sourcing, or parallel project complexity, which could extend losses and eventually force more funding or dilution if timelines slip materially.

    The Nuclear Regulatory Commission sign off on the Principal Design Criteria for the Aurora Powerhouse is the clearest operational link to this latest news. That decision narrows technical uncertainty around Oklo’s compact reactor concept and gives the business a more defined path for licensing work, which matters for large customers that need confidence before committing to power or heat contracts.

    Paired with the DOE’s Launch Pad support for Groves 2 Forge, the Aurora criteria decision frames two potential future cash engines, one from electricity and one from isotopes like lutetium 177. For investors watching catalysts, the focus now turns to whether these programs move from design and pilot activity into licensed, funded projects without major overruns, since any slippage would feed directly into the existing execution and financing risks.

    What The Current Analyst Framework Implies For Oklo

    Analysts sketch an aggressive ramp for Oklo’s top line, with consensus modeling revenue expanding at about 318% per year over the next three years. That set of assumptions uses a wide profit swing as the anchor, moving from a reported loss of US$152.8 million in earnings today to forecast consensus earnings of US$13.2 million by 2029, which is an earnings increase of about US$166 million. The same models pin 2029 revenue at US$88.4 million and they treat that figure as the reference point for fair value work on the stock.

    Oklo's narrative projects US$88.4 million revenue and US$13.2 million earnings by 2029. This requires very large yearly revenue growth of about 318% and an earnings increase of about US$166 million from a loss of US$152.8 million today.

    Uncover why Oklo's fair value indicates a 171% potential upside to its current price that could narrow quickly.

    NYSE:OKLO 1-Year Stock Price Chart
    NYSE:OKLO 1-Year Stock Price Chart

    Exploring Other Perspectives

    You are seeing one optimistic twist on Oklo here. The most bullish analysts were already modeling revenue of about US$129.1 million and earnings of US$19.4 million by 2029, compared with consensus at US$88.4 million and US$13.2 million. That group treats faster medical isotope traction as a key upside swing factor, so Groves 2 Forge could prompt big revisions.

    Explore 8 other Oklo fair value estimates, including one that suggests as much as 260% upside from the current price.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own research and judgment.

    Looking For More Investment Ideas Beyond Oklo?

    Oklo may sit at the center of your research right now, but your portfolio decisions will usually be stronger when you compare it with a few very different opportunities side by side. The Simply Wall St Screener helps you quickly filter for companies that match the risk, return, and quality profile you care about, then track how they evolve over time.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.